P897: UPDATED RESULTS FROM THE ONGOING PHASE 1 STUDY OF ELRANATAMAB, A BCMA TARGETED T-CELL REDIRECTING IMMUNOTHERAPY, FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA. (23rd June 2022)

Record Type:
Journal Article
Title:
P897: UPDATED RESULTS FROM THE ONGOING PHASE 1 STUDY OF ELRANATAMAB, A BCMA TARGETED T-CELL REDIRECTING IMMUNOTHERAPY, FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA. (23rd June 2022)
Main Title:
P897: UPDATED RESULTS FROM THE ONGOING PHASE 1 STUDY OF ELRANATAMAB, A BCMA TARGETED T-CELL REDIRECTING IMMUNOTHERAPY, FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Authors:
Dalovisio, A.
Bahlis, N.
Raje, N.
Costello, C.
Dholaria, B.
Solh, M.
Levy, M.
Tomasson, M.
Dube, H.
Damore, M.
Jiang, S.
Basu, C.
Skoura, A.
Chan, E.
Trudel, S.
Jakubowiak, A.
Chu, M.
Gasparetto, C.
Sebag, M.
Lesokhin, A.
Abstract:
Is Part Of:
HemaSphere. Volume 6(2022)Supplement 3
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Issue Display:
Volume 6, Issue 3 (2022)
Year:
2022
Volume:
6
Issue:
3
Issue Sort Value:
2022-0006-0003-0000
Page Start:
788
Page End:
789
Publication Date:
2022-06-23
Subjects:
Hematology -- Periodicals
616.15005
Journal URLs:
https://journals.lww.com/hemasphere/pages/default.aspx ↗
http://journals.lww.com/pages/default.aspx ↗
DOI:
10.1097/01.HS9.0000846460.44039.3d ↗
Languages:
English
ISSNs:
2572-9241
Deposit Type:
Legaldeposit
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store
Ingest File:
22732.xml